Clear Street Raises Delcath Systems, Inc. (DCTH) Target to $29, Maintains Buy Rating

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 9, Clear Street raised its price target on Delcath Systems, Inc. (NASDAQ:DCTH) to $29 from $28 while maintaining a Buy rating following the release of preliminary fourth-quarter results. The firm noted that its product Hepzato has become a steadier revenue contributor, with improved predictability and sufficient cash generation to support expansion into additional indications.

On the same day, Delcath Systems, Inc. (NASDAQ:DCTH) reported preliminary, unaudited results showing expected fourth-quarter revenue of approximately $20.7 million and full-year 2025 revenue of $85.2 million. Performance was driven primarily by Hepzato sales, which totaled about $19.0 million for the quarter and $78.8 million for the year, with Chemosat contributing the remainder. The company reported strong operating cash flow and minimal leverage, supporting internal funding of clinical programs and a previously announced share repurchase plan.

Delcath Systems, Inc. (NASDAQ:DCTH) was founded on August 5, 1988, and is headquartered in Queensbury, New York. The company develops interventional oncology therapies for primary and metastatic liver cancers, including the Hepzato and Chemosat Hepatic Delivery System.

While we acknowledge the potential of DCTH as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.